Creating new treatments for tumors linked to VHL mutations
Developing a Translation Pipeline for VHL Mutant Malignancies
This study is looking for new treatments for patients with tumors linked to the von Hippel-Lindau (VHL) gene mutation, and it aims to test new drugs that could help fight these tumors, giving patients a chance to join clinical trials for these exciting therapies.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11039987 on NIH RePORTER |
What this research studies
This research focuses on developing a pipeline to bring new therapies to patients with tumors associated with the von Hippel-Lindau (VHL) gene mutation. It investigates how the VHL gene's inactivation leads to tumor formation and aims to test inhibitors that target a specific transcription factor involved in this process. By collaborating with leading cancer centers, the project seeks to enhance understanding of these tumors and facilitate the clinical development of new drugs. Patients may have the opportunity to participate in clinical trials testing these innovative treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with VHL-associated malignancies, particularly those with clear cell renal cell carcinoma.
Not a fit: Patients without VHL mutations or those with unrelated tumor types may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with VHL-related tumors, improving their outcomes.
How similar studies have performed: Previous studies have shown promising results with similar approaches, particularly in targeting the HIF2α transcription factor in VHL-related tumors.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Mcdermott, David — Beth Israel Deaconess Medical Center
- Study coordinator: Mcdermott, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.